These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12794534)

  • 1. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 2. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 3. New directions in the treatment of patients with chronic myeloid leukemia: introduction.
    Baccarani M
    Semin Hematol; 2009 Apr; 46(2 Suppl 3):S1-4. PubMed ID: 19621542
    [No Abstract]   [Full Text] [Related]  

  • 4. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 5. Why doesn't imatinib cure chronic myeloid leukemia?
    Redner RL
    Oncologist; 2010; 15(2):182-6. PubMed ID: 20124443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current state and the future of molecular target drugs: lessons learned from the success of imatinib].
    Yamada H
    Nihon Yakurigaku Zasshi; 2008 Dec; 132(6):339-42. PubMed ID: 19075528
    [No Abstract]   [Full Text] [Related]  

  • 7. STI-571 in chronic myelogenous leukaemia.
    Tsao AS; Kantarijian H; Talpaz M
    Br J Haematol; 2002 Oct; 119(1):15-24. PubMed ID: 12358949
    [No Abstract]   [Full Text] [Related]  

  • 8. 3. Imatinib therapy in chronic myelogenous leukemia.
    Jinnai I
    Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
    Xu XH; Huang LS; Yang J; Yu T; Tong JF; Yuan XG; Zhao XY
    Leuk Lymphoma; 2013 Jan; 54(1):195-7. PubMed ID: 22574970
    [No Abstract]   [Full Text] [Related]  

  • 10. Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.
    Takahashi N; Kameoka Y; Tagawa H; Saitoh H; Yoshioka T; Fujishima N; Kitabayashi A; Takahashi K; Hirokawa M; Sawada K
    Int J Hematol; 2010 Oct; 92(3):559-61. PubMed ID: 20838959
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
    Li YF; Liu X; Liu DS; Din BH; Zhu JB
    Leuk Lymphoma; 2009 Nov; 50(11):1889-91. PubMed ID: 19860613
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
    Mesa RA; Steensma DP; Hoyer J; Ketterling RP
    Br J Haematol; 2003 Oct; 123(2):366-7. PubMed ID: 14531922
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 14. Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.
    Zeidan A; Kakati S; Anderson B; Barcos M; Wetzler M
    Cancer Genet Cytogenet; 2007 Jul; 176(2):169-71. PubMed ID: 17656263
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of chronic myelogenous leukemia by using imatinib].
    Jinnai I
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
    Koca E; Cetiner D; Goker H; Aksu S; Ozcebe OI; Haznedaroglu IC; Turgan C
    Clin Nephrol; 2005 Oct; 64(4):324-6. PubMed ID: 16240908
    [No Abstract]   [Full Text] [Related]  

  • 17. Pregnancy outcome of two patients treated with imatinib.
    Prabhash K; Sastry PS; Biswas G; Bakshi A; Prasad N; Menon H; Parikh PM
    Ann Oncol; 2005 Dec; 16(12):1983-4. PubMed ID: 16100234
    [No Abstract]   [Full Text] [Related]  

  • 18. Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
    Yilmaz M; Demirhan O; Kuçukosmanoglu E; Pehlivan M; Okan V; Balat O; Pehlivan S
    Leuk Lymphoma; 2007 Dec; 48(12):2454-6. PubMed ID: 18067024
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. After imatinib: new hopes for chronic myeloid leukaemia.
    Bradbury J
    Drug Discov Today; 2005 Apr; 10(8):536-7. PubMed ID: 15837592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.